Effect of a high-egg diet on cardiometabolic risk factors in people with type 2 diabetes: the Diabetes and Egg (DIABEGG) Study-randomized weight-loss and follow-up phase

Am J Clin Nutr. 2018 Jun 1;107(6):921-931. doi: 10.1093/ajcn/nqy048.


Background: Some country guidelines recommend that people with type 2 diabetes (T2D) limit their consumption of eggs and cholesterol. Our previously published 3-mo weight-maintenance study showed that a high-egg (≥12 eggs/wk) diet compared with a low-egg diet (<2 eggs/wk) did not have adverse effects on cardiometabolic risk factors in adults with T2D.

Objective: The current study follows the previously published 3-mo weight-maintenance study and assessed the effects of the high-egg compared with the low-egg diets as part of a 3-mo weight-loss period, followed by a 6-mo follow-up period for a total duration of 12 mo.

Design: Participants with prediabetes or T2D (n = 128) were prescribed a 3-mo daily energy restriction of 2.1 MJ and a macronutrient-matched diet and instructed on specific types and quantities of foods to be consumed, with an emphasis on replacing saturated fats with monounsaturated and polyunsaturated fats. Participants were followed up at the 9- and 12-mo visits.

Results: From 3 to 12 mo, the weight loss was similar (high-egg compared with low-egg diets: -3.1 ± 6.3 compared with -3.1 ± 5.2 kg; P = 0.48). There were no differences between groups in glycemia (plasma glucose, glycated hemoglobin, 1,5-anhydroglucitol), traditional serum lipids, markers of inflammation (high-sensitivity C-reactive protein, interleukin 6, soluble E-selectin), oxidative stress (F2-isoprostanes), or adiponectin from 3 to 12 mo or from 0 to 12 mo.

Conclusions: People with prediabetes or T2D who consumed a 3-mo high-egg weight-loss diet with a 6-mo follow-up exhibited no adverse changes in cardiometabolic markers compared with those who consumed a low-egg weight-loss diet. A healthy diet based on population guidelines and including more eggs than currently recommended by some countries may be safely consumed. This trial is registered at http://www.anzctr.org.au/ as ACTRN12612001266853.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Blood Glucose
  • C-Reactive Protein / metabolism
  • Cardiovascular Diseases / diet therapy*
  • Cardiovascular Diseases / prevention & control
  • Diabetes Mellitus, Type 2 / diet therapy*
  • Diet, Reducing*
  • Eggs*
  • F2-Isoprostanes / blood
  • Female
  • Follow-Up Studies
  • Heart Diseases / diet therapy
  • Humans
  • Interleukin-6 / blood
  • Interleukin-6 / metabolism
  • Lipids / blood
  • Male
  • Middle Aged
  • Obesity / blood
  • Obesity / diet therapy
  • Risk Factors
  • Selectins / blood
  • Treatment Outcome
  • Weight Loss*


  • Blood Glucose
  • F2-Isoprostanes
  • Interleukin-6
  • Lipids
  • Selectins
  • C-Reactive Protein

Associated data

  • ANZCTR/ACTRN12612001266853